The role of telavancin in the treatment of MRSA infections in hospital

Expert Opinion on Investigational Drugs

Volumn 18, Issue 4, 2009, Pages 521-529

  Bassetti, Matteo ^a   Mikulska, Malgorzata ^a   Righi, Elda ^a   Nicolini, Laura ^a   Viscoli, Claudio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Hospital acquired pneumonia; MRSA; Skin and soft tissue infection; Telavancin; Vancomycin; VISA; VRE

Indexed keywords

AZTREONAM; CLOXACILLIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; METRONIDAZOLE; NAFCILLIN; OXACILLIN; TEICOPLANIN; TELAVANCIN; VANCOMYCIN;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; CREATININE BLOOD LEVEL; DIZZINESS; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DYSGEUSIA; ENTEROCOCCUS; FLUSHING; HEADACHE; HOSPITAL INFECTION; HUMAN; HYPOKALEMIA; INJECTION SITE REACTION; INSOMNIA; KIDNEY DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROALBUMINURIA; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PRURITUS; REVIEW; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; STREPTOCOCCUS PNEUMONIAE; TASTE DISORDER; THROMBOCYTE COUNT; URTICARIA; VENTILATOR ASSOCIATED PNEUMONIA; VOMITING;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS;

EID: 67649631214     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780902845630     Document Type: Review

References (47)

1. Hegde SS, Reyes N, Skinner R, Difuntorum S. Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus. J Antimicrob Chemother 2008;61(1):169-172
2. Madrigal AG, Basuino L, Chambers HF. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillinresistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005;49(8):3163-3165 (Pubitemid 41060554)
3. Reyes N, Skinner R, Benton BM, et al. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006;58(2):462-465 (Pubitemid 44294968)
4. Reyes N, Skinner R, Kaniga K, et al. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49(10):4344-4346 (Pubitemid 41400983)
5. Yin LY, Calhoun JH, Thomas TS, Wirtz ED. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model. J Antimicrob Chemother 2009;63(2):357-360
6. Miro JM, Garcia-de-la-Maria C, Armero Y, et al. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2007;51(7):2373-2377 (Pubitemid 47047313)
7. Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51(26):565-567
8. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004;38(4):521-528 (Pubitemid 38250962)
9. Leadbetter MR, Adams SM, Bazzini B, et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J Antibiot (Tokyo) 2004;57(5):326-336 (Pubitemid 38811717)
10. Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006;58(2):338-343 (Pubitemid 44294945)
11. King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentrationdependent anti-infective with multiple mechanisms of action against gram-positive bacteria. J Antimicrob Chemother 2004;53(5):797-803 (Pubitemid 38660281)
12. Pace JL, Krause K, Johnston D, et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003;47(11):3602-3604
13. Saravolatz LD, Pawlak J, Johnson LB. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2007;60(2):406-409 (Pubitemid 47243894)
14. Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006;50(3):862-867 (Pubitemid 43327787)
15. Hatano K, Matsuzaki K, Sato Y, et al. In vitro antimicrobial activity of telavancin against methicillin-resistant Staphylococcus aureus clinical isolates from Japan 2006. J Antibiot (Tokyo) 2007;60(11):709-712
16. Krause KM, Renelli M, Difuntorum S, et al. In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob Agents Chemother 2008;52(7):2647-2652
17. Draghi DC, Benton BM, Krause KM, et al. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-2005 Prospective European Surveillance Initiative. J Antimicrob Chemother 2008;62(1):116-121
18. Draghi DC, Benton BM, Krause KM, et al. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother 2008;52(7):2383-2388 (Pubitemid 351915666)
19. Jansen WT, Verel A, Verhoef J, Milatovic D. In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe. Antimicrob Agents Chemother 2007;51(9):3420-3424
20. Bae IG, Stryjewski ME, Lalani T, et al. Associations between patient outcome and bacterial genotype of S. aureus isolates from a multinational trial of hospital-acquired pneumonia. [abstract K-493]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Washington, DC, October 25-28 2008
21. Lapalnte KL, Mermel LA. In vitro Activity of Telavancin (TEL) & Vancomycin (VAN) against biofilm-producing Staphylococcus aureus (SA), S. epidermidis (SE) & Enterococcus faecalis (EF). [abstract F1-362]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Washington, DC, October 25-28 2008
22. Baquero F. Pneumococcal resistance to beta-lactam antibiotics: a global geographic overview. Microb Drug Resist 1995;1(2):115-120
23. Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am J Med 1998;104(5A):7S-10S (Pubitemid 28299973)
24. McCormick AW, Whitney CG, Farley MM, et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med 2003;9(4):424-430 (Pubitemid 36460076)
25. Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrob Agents Chemother 2004;48(6):2149-2152
26. Shaw JP, Seroogy J, Kaniga K, et al. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005;49(1):195-201 (Pubitemid 40065793)
27. Shaw JP, McCullough J, Jaw Tsai S. Protein binding of 14C telavancin in plasma and human skin blister fluid. [abstract A-1878]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Washington, DC, October 25-28 2008
28. Duchin K, Shaw J, Spencer E, et al. Single dose pharmacokinetics (PK) of telavancin (TLV) in subjects with renal dysfunction. [abstract P-1028]. 14th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); Prague, Czech Republic, May 1-4, 2004
29. Duchin K, Shaw J, Spencer E, et al. Single dose pharmacokinetics (PK) of telavancin (TLV) in healthy elderly subjects. [abstract P-1027]. 14th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); Prague, Czech Republic, May 1-4, 2004
30. Wong SL, Shaw JP, Barriere S, et al. Pharmacokinetics of intravenous telavancin in subjects with hepatic impairment. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); San Francisco, CA, September 17-20 2006
31. Sun HK, Duchin K, Nightingale CH, et al. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother 2006;50(2):788-790 (Pubitemid 43191003)
32. Gotfried MH, Shaw JP, Benton BM, et al. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother 2008;52(1):92-97 • Interesting data on lung penetration.
33. Lodise TP Jr, Gotfried M, Barriere S, Drusano GL. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 2008;52(7):2300-2304 (Pubitemid 351915656)
34. Hegde SS, Reyes N, Wiens T, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother 2004;48(8):3043-3050 (Pubitemid 38989173)
35. Odenholt I, Lowdin E, Cars O. Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model. Antimicrob Agents Chemother 2007;51(9):3311-3316 (Pubitemid 350067545)
36. Bowker KE, Noel AR, Tomaselli SG, Macgowan AP. Pharmacodynamics of Telavancin: relationship of AUC/MIC to antibacterial effect and emergence of resistance. [abstract A-980]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Washington, DC, October 25-28 2008
37. Gander S, Kinnaird A, Finch R. Telavancin: in vitro activity against staphylococci in a biofilm model. J Antimicrob Chemother 2005;56(2):337-343 (Pubitemid 41158522)
38. Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, et al. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycinresistant Staphylococcus aureus. J Antimicrob Chemother 2006;58(6):1177-1184 (Pubitemid 44884136)
39. Barcia-Macay M, Mouaden F, Mingeot-Leclercq MP, et al. Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts). J Antimicrob Chemother 2008;61(6):1288-1294 (Pubitemid 351760774)
40. Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005;40(11):1601-1607 (Pubitemid 40720810)
41. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008;46(11):1683-1693 • More recent data on efficacy in cSSSI. (Pubitemid 351706765)
42. Wilson SE, O'Riordan W, Hopkins A, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. Am J Surg 2008. [Epub ahead of print] doi:10.1016/j.amjsurg.2008.05.012
43. Dunbar L, Sibley D, Hunt J, et al. Recurrence of skin infections in patients treated with telavancin versus vancomycin for complicated skin and soft tissue infections in a New Orleans emergency department. In: Care C, editor. 28th International Symposium on Intensive Care and Emergency Medicine. Brussels, Belgium: P29 (doi: 10.1186/cc6250), 2008
44. Rubinstein E, Corey GR, Stryjewski ME, et al. Telavancin for hospital-acquired pneumonia, including ventilator-associated pneumonia: the ATTAIN studies. [abstract 075]. 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); Spain, Barcelona, April 19-22 2008 • Data on the treatment of hospital-acquired pneumonia.
45. Rubinstein E, Corey GR, Stryjewski ME, et al. Telavancin for Treatment of Hospital-Acquired Pneumonia (HAP) Caused by MRSA and MSSA: the ATTAIN studies. [abstract K-530]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Washington, DC, October 25-28 2008
46. Rubinstein E, Corey GR, Boucher HW, et al. Telavancin for the treatment of hospital-acquired pneumonia in severely Ill and older patients: the ATTAIN studies. [abstract k-529]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Washington, DC, October 25-28 2008
47. Barriere S, Genter F, Spencer E, et al. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol 2004;44(7):689-695 (Pubitemid 38765930)